| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
The mission of the Society is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy. Learn more at www.sts.org.
eNATAL is a Shawnee, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chrysalis Health is proud to be one of the leading providers of behavioral healthcare services for children, adolescents, adults, and families throughout Florida.
Practice Velocity is a Belvidere, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.